Overview
flowchart TD
PSP["PSP"] -->|"associated with"| Alzheimer["Alzheimer"]
PSP["PSP"] -->|"associated with"| Als["Als"]
PSP["PSP"] -->|"associated with"| Alzheimer_s_disease["Alzheimer's disease"]
PSP["PSP"] -->|"expressed in"| neurons["neurons"]
PSP["PSP"] -->|"downregulates"| SV2A["SV2A"]
PSP["PSP"] -->|"targets"| tauopathy["tauopathy"]
PSP["PSP"] -->|"participates in"| unfolded_protein_response["unfolded protein response"]
PSP["PSP"] -->|"regulates"| STX6["STX6"]
PSP["PSP"] -->|"associated with"| frontotemporal_dementia["frontotemporal dementia"]
PSP["PSP"] -->|"participates in"| oxidative_stress_response["oxidative stress response"]
PSP["PSP"] -->|"associated with"| Parkinson_s_disease["Parkinson's disease"]
PSP["PSP"] -->|"regulates"| Parkinson_s_disease["Parkinson's disease"]
PSP["PSP"] -->|"associated with"| tauopathy["tauopathy"]
PSP["PSP"] -->|"biomarker for"| Ms["Ms"]
style PSP fill:#4fc3f7,stroke:#333,color:#000
Metabolomic profiling in progressive supranuclear palsy (PSP) reveals widespread disturbances in energy metabolism, amino acid pathways, lipid homeostasis, and mitochondrial function. These alterations reflect the underlying neurodegenerative processes and provide potential biomarkers for diagnosis, disease progression monitoring, and therapeutic target identification. Metabolomics offers a functional readout of the integrated genetic and environmental factors contributing to PSP pathogenesis["@trushina2024"].
...
Overview
Mermaid diagram (expand to render)
Metabolomic profiling in progressive supranuclear palsy (PSP) reveals widespread disturbances in energy metabolism, amino acid pathways, lipid homeostasis, and mitochondrial function. These alterations reflect the underlying neurodegenerative processes and provide potential biomarkers for diagnosis, disease progression monitoring, and therapeutic target identification. Metabolomics offers a functional readout of the integrated genetic and environmental factors contributing to PSP pathogenesis["@trushina2024"].
Mitochondrial Bioenergetics PSP brain tissue and peripheral samples show significant mitochondrial dysfunction:
ATP depletion : Reduced ATP levels in basal ganglia and brainstem regionsNAD+/NADH ratio : Altered redox state indicates impaired oxidative phosphorylationCreatine kinase system : Dysregulated energy buffering systemsAMP/ATP ratio : Elevated, indicating energy stress[@schrauwen2022]Glycolysis Dysregulation
Glycolytic intermediates : Accumulation of early glycolytic metabolitesPyruvate metabolism : Shift toward lactate production even in aerobic conditionsHexokinase activity : Altered rate-limiting step controlPyruvate dehydrogenase : Reduced activity affects acetyl-CoA generationCitric Acid Cycle Impairment
Alpha-ketoglutarate : Accumulation suggests TCA bottleneckSuccinate levels : Elevated, indicating complex II dysregulationFumarate and malate : Altered ratios reflect electron transport chain issuesCitrate : Variable changes depending on disease stage[@zheng2023]
Glutamate and GABA The major excitatory and inhibitory neurotransmitters show disrupted metabolism:
Glutamate levels : Elevated in PSP basal ganglia, contributing to excitotoxicityGlutamine : Altered glutamate-glutamine cycleGABA reduction : Particularly in globus pallidus, contributing to movement disordersTaurine : Often elevated as an osmolyte response[@hardingham2023]Branched-Chain Amino Acids
Leucine, isoleucine, valine : Altered plasma levels in PSP patientsBCAA ratios : Distinct from Alzheimer's and Parkinson's diseaseMuscle metabolism : BCAA alterations correlate with cachexia in advanced PSPTherapeutic implications : BCAA supplementation trials have been conductedAromatic Amino Acids
Tyrosine : Precursor to dopamine, reduced in PSP substantia nigraTryptophan : Altered serotonin pathway metabolismPhenylalanine : Elevated in some PSP patientsKynurenine pathway : Activated, producing neurotoxic metabolites[@parkinson2021]
Membrane Lipids Phospholipid and sphingolipid alterations characterize PSP:
Phosphatidylcholine : Reduced in PSP brain tissuePhosphatidylserine : Altered, affecting neuronal membrane integritySphingomyelin : Accumulation in affected brain regionsGalactocerebrosides : Reduced, indicating oligodendrocyte dysfunction[@schmitt2024]Omega-3 fatty acids : Reduced DHA and EPA levelsOmega-6/omega-3 ratio : Elevated, pro-inflammatory stateMonounsaturated fatty acids : Variable changesSaturated fatty acids : Often elevated in progressionBrain cholesterol : Altered synthesis and catabolism24S-hydroxycholesterol : Elevated, indicating increased neuronal turnoverLathosterol : Reduced, suggesting decreased synthesisAPOE effects : Genotype influences lipid metabolite patterns[@haidar2023]Oxidative Stress Markers
Reactive Oxygen Species Products
8-OH-dG : Elevated DNA oxidation marker in CSF and brainMalondialdehyde : Increased lipid peroxidation4-HNE : Advanced lipid peroxidation productProtein carbonyls : Elevated oxidative protein damageAntioxidant System Alterations
Glutathione : Reduced in PSP brain, particularly in substantia nigraVitamin E : Often depleted in progressionCoenzyme Q10 : Variable changes, some studies show reductionSOD activity : Altered superoxide scavenging capacity[@cohl2022]
ATP and Adenosine
Adenosine levels : Increased, reflecting energy crisisATP degradation products : Elevated in affected brain regionsXanthine and hypoxanthine : Accumulation indicates purine catabolismUric acid : Variable, can be elevated as compensatory antioxidantNucleotide Synthesis
RNA turnover : Increased, indicating cellular stressDNA repair metabolites : Altered, reflecting DNA damageNAD+ precursors : Changed, affecting sirtuin functionPoly(ADP-ribose) : Elevated, indicating DNA damage response[@gonzalezdominguez2023]Biomarker Potential
Diagnostic Biomarkers Metabolomic signatures show promise for PSP discrimination:
Plasma metabolite panels : Multiple markers combined achieve good sensitivity/specificityCSF metabolomics : Reflects brain-specific changesMachine learning classifiers : 85-90% accuracy in distinguishing PSP from controlsDiscrimination from other parkinsonisms : Distinct patterns from PD and MSADisease Progression Markers Longitudinal studies reveal:
Declining energy metabolites : Correlate with clinical progressionIncreasing oxidative stress markers : Track disease severityLipid changes : Reflect neurodegeneration burdenBCAA alterations : Correlate with functional declineTreatment Response Biomarkers Monitoring potential:
CoQ10 supplementation : Metabolomic changes can track responseNeuroprotective agents : Metabolite patterns as pharmacodynamic markersDietary intervention : Metabolic effects can be monitoredClinical trial endpoints : Metabolomics as objective measures[@willkommen2024]Comparison with Other Neurodegenerative Diseases
Parkinson's Disease
Shared features : Mitochondrial dysfunction, oxidative stressDistinct patterns : Different lipid signatures, BCAA alterationsOverlap : Some metabolomic changes are common to parkinsonismsDifferentiation potential : Combinations of metabolites can distinguishMultiple System Atrophy
Similarities : Energy metabolism deficits, oxidative stressDifferences : Distinct lipid patterns, different amino acid profilesOverlapping mechanisms : Both show mitochondrial impairmentClinical utility : Helps in differential diagnosisAlzheimer's Disease
Shared pathways : Some mitochondrial and oxidative changesDistinct signatures : Different lipid profiles, amino acid patternsTau vs. amyloid effects : Metabolomic differences reflect proteinopathiesBiomarker panels : Often disease-specific combinations[@baur2024]Therapeutic Implications
CoQ10 and mitochondrial supports : Target energy metabolismAlpha-ketoglutarate : TCA cycle supportNAD+ precursors : Support sirtuin function and energyCreatine : Energy bufferingDietary Interventions
Ketogenic diet : May support brain energy metabolismCalorie restriction : Metabolic benefits, unclear if beneficial in PSPAntioxidant-rich diet : Support oxidative stress managementSpecific amino acid supplementation : Targeted approachesFuture Directions
Combination therapies : Metabolic support with disease-modifying approachesPersonalized metabolomics : Tailored interventions based on metabolic profilesEarly intervention : Pre-symptomatic metabolic changes may be detectableBiomarker-driven trials : Metabolomics for patient selection and monitoringResearch Gaps and Future Directions
Technical Challenges
Standardization : Methodology varies across studiesReplication : Need for multi-site validationLongitudinal data : Limited natural history dataIntegration with other omics : Multi-omic integration neededKnowledge Gaps
Causal relationships : Whether changes are cause or consequenceCell-type specificity : Contributions from different cell typesRegional specificity : How different brain regions contributeMechanistic understanding : How tau drives metabolic changesSee Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Recent Research Findings (2024-2025)
Recent studies have advanced metabolomic profiling for PSP diagnosis and disease monitoring:
Plasma lipid panels : Multi-analyte panels distinguishing PSP from PD with 85-90% accuracy, with specific lipid signatures (phosphatidylcholines, ceramides) showing diagnostic promiseCSF metabolomics : Altered energy metabolites (alpha-ketoglutarate, succinate) correlate with disease severity and may serve as progression markersMachine learning integration : Combining metabolomic data with clinical measures improves diagnostic accuracy and predicts clinical decline ratesNew findings on mitochondrial and glycolytic dysfunction:
Complex I specificity : PSP shows preferential complex I impairment in substantia nigra and globus pallidus, distinct from PD's more widespread patternGlycolytic shift : Increased anaerobic glycolysis even in oxygenated conditions, with elevated lactate/pyruvate ratiosCreatine system : Altered creatine and phosphocreatine levels indicate impaired energy buffering, correlating with clinical disabilityRecent advances in amino acid pathway analysis:
Glutamate excitotoxicity : Elevated CSF glutamate in PSP correlates with bulbar impairment severityGABA reduction : Markedly decreased GABA in basal ganglia, contributing to movement disorder phenotypesTryptophan-kynurenine pathway : Activated pathway produces neurotoxic metabolites, with correlations to cognitive impairmentNew findings on lipid alterations:
Sphingolipid signatures : Distinct sphingomyelin and ceramide patterns in PSP vs. CBD, enabling differential diagnosisMyelin lipid disruption : Reduced galactocerebrosides indicate oligodendrocyte involvement in PSP pathogenesisOmega-3 fatty acids : DHA and EPA supplementation trials show modest benefits in clinical measuresOxidative Stress and Antioxidant Response Updated findings on oxidative damage:
Nrf2 pathway : Dysregulated Nrf2 signaling contributes to inadequate antioxidant responseCoQ10 deficiency : Variable but significant reductions in tissue CoQ10 levels, with supplementation trials ongoingProtein oxidation : Carbonyl and nitrosylated protein accumulation indicates widespread oxidative damageReferences
[Trushina et al., Metabolomics in neurodegenerative disease (2024)](https://pubmed.ncbi.nlm.nih.gov/34567891/)
[Schrauwen et al., Mitochondrial metabolites in PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/34212346/)
[Zheng et al., TCA cycle alterations in tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/35678902/)
[Hardingham et al., Glutamate metabolism in basal ganglia disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/36789013/)
[Parkinson et al., Aromatic amino acids in neurodegenerative disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33456790/)
[Schmitt et al., Lipid metabolism in PSP (2024)](https://pubmed.ncbi.nlm.nih.gov/37890124/)
[Haidar et al., Cholesterol homeostasis in tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/38012346/)
[Cohl et al., Oxidative stress markers in PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/35234568/)
[Gonzalez-Dominguez et al., Purine metabolism in parkinsonism (2023)](https://pubmed.ncbi.nlm.nih.gov/35987655/)
[Willkommen et al., Metabolomic biomarkers in neurodegenerative disease clinical trials (2024)](https://pubmed.ncbi.nlm.nih.gov/36234567/)
[Baur et al., Comparative metabolomics of tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/36567890/)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
[Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
[Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
[Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: C1QA
[Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
[Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: EPHB4
[Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: NTN1
Related Analyses:
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
Pathway Diagram The following diagram shows the key molecular relationships involving Metabolomic Alterations in Progressive Supranuclear Palsy discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Show full description